Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature
Authors
Keywords
Palmoplantar erythrodysesthesia, Hand-foot syndrome, Hand-foot skin reaction, Toxic erythema of chemotherapy, Tyrosine kinase inhibitor, Vascular endothelial growth factor
Journal
SUPPORTIVE CARE IN CANCER
Volume 23, Issue 6, Pages 1827-1835
Publisher
Springer Nature
Online
2014-12-04
DOI
10.1007/s00520-014-2520-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Oral Anticancer Drugs: How Limited Dosing Options and Dose Reductions May Affect Outcomes in Comparative Trials and Efficacy in Patients
- (2014) Vinay Prasad et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular targeted therapy for hepatocellular carcinoma: Current and future
- (2014) Jung Woo Shin WORLD JOURNAL OF GASTROENTEROLOGY
- Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: A new treatment for metastatic soft tissue sarcoma
- (2013) Girolamo Ranieri et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Targeting angiogenesis in renal cell carcinoma
- (2013) Edwin M Posadas et al. EXPERT OPINION ON PHARMACOTHERAPY
- The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis
- (2013) Alyssa Fischer et al. INVESTIGATIONAL NEW DRUGS
- Hand-Foot Skin Reaction is Associated with the Clinical Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Sorafenib
- (2013) K. Nakano et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma
- (2012) Joo Ho Lee et al. CANCER
- Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance
- (2012) Suneet Shukla et al. DRUG RESISTANCE UPDATES
- Cediranib: a VEGF receptor tyrosine kinase inhibitor
- (2012) Marina Sahade et al. Future Oncology
- Risk of Rash in Cancer Patients Treated with Vandetanib: Systematic Review and Meta-Analysis
- (2012) Alyx C. Rosen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors
- (2012) M. McTigue et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies
- (2011) Yevgeniy Balagula et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Presentation and Management of Hand-Foot Skin Reaction Associated with Sorafenib in Combination with Cytotoxic Chemotherapy: Experience in Breast Cancer
- (2011) P. Gomez et al. ONCOLOGIST
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy
- (2009) N. S. Azad et al. CLINICAL CANCER RESEARCH
- Risk of Hand-Foot Skin Reaction with the Multitargeted Kinase Inhibitor Sunitinib in Patients with Renal Cell and Non–Renal Cell Carcinoma: A Meta-analysis
- (2009) David Chu et al. Clinical Genitourinary Cancer
- Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib
- (2009) Adam D. Lipworth et al. ONCOLOGY
- Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis
- (2008) David Chu et al. ACTA ONCOLOGICA
- Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib
- (2008) M. E. Lacouture et al. ANNALS OF ONCOLOGY
- Role of platelet-derived growth factors in physiology and medicine
- (2008) J. Andrae et al. GENES & DEVELOPMENT
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
- Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib
- (2008) M. E. Lacouture et al. ONCOLOGIST
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started